Mast Cell Profile in Benign and Malignant Prostatic Lesions
Keywords:
Mast Cells, Benign Prostatic Hyperplasia, Adenocarcinoma
Abstract
Introduction: Mast cells have an important role in innate and adaptive immunity. There role in tumour pathology is under investigation due to studies linking them to angiogenesis, tissue remodeling and stromal immunomodulation. Reports suggest that they can exert both pro or anti tumour effects. The role of mast cells may be influenced by its location in the lesion. In the present study, the number and distribution of mast cells in both benign and malignant prostatic lesions were recorded. Methodology: Fifty seven patients of benign prostatic hyperplasia (BPH) and 43 patients of adenocarcinoma (Ca) were the subjects of the study. Inflammatory conditions of prostate like prostatitis and other malignancies of prostate like sarcoma, transitional cell carcinoma etc were excluded from the study. This was a descriptive study with purposive sampling. Histological diagnosis was made by examining sections stained with Haematoxylin and Eosin. Additional sections from the same block were stained for mast cells using Giemsa stains as per standard protocol. Mast cell count was done in minimum 6 random high power microscopy field in four different regions viz., intraglandular, periglandular, stromal and perivascular regions for BPH and intratumoral, peritumoral, stromal and perivascular regions for Ca. Results were analysed statistically. Results: In BPH cases showed a significantly higher number of mast cells in stromal as well as periglandular areas followed by perivascular area. Only few mast cells were observed in intraglandular area. Similar was the observations in adenocarcinoma cases where the maximum number of mast cells were concentrated in the stromal and perilesional area. The number of mast cells in stroma of BPHwas higher as compared to that of adenocarcinoma. In rest of the areas, the numbers were comparable. Conclusion: This study showed no remarkable difference in the number and distribution of mast cells in benign and malignant prostatic lesions. There is paucity of such studies in the literature and the possible utility of mast cell count to differentiate malignant from benign and atypical conditions needs further evaluation.References
1. Barret KE, Ganong WF. Immunity, infection and inflammation In : Ganong’s Review
of medical physiology. New York: McGraw-Hill Medical: 2005.p.63-78.
2. Globa T, Şaptefrţi L, Ceauşu RA, Gaje P, Cimpean AM, Raica M. Mast cell
phenotype in benign and malignant tumors of the prostate. Pol JPathol 2014;
2:147–153.
3. Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth.
Trends Immunol 2004; 25:235–241.
4. Gupta RK. Mast cell variations in prostate and urinary bladder. Arch Pathol
1970; 89:302–305.
5. Sari A, Serel TA, Çandir Ö, Öztürk A, Kosar A. Mast cell variations in tumour tissue
and with histopathological grading in specimens of prostatic adenocarcinoma. BJU
Int 1999; 84: 851-853
6. Strasner A, Karin M. Immune infiltration and prostate cancer. Front Oncol 2015;
5:128.
7. Crivellato E, Nico B, Ribatti D. Mast cell contribution to tumor angiogenesis: a clinical
approach.Eur Cytokine Netw 2009; 20:197–206.
8.Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M, Rigoni A et al. Mast cell
targeting hampers prostate adenocarcinoma development but promotes the
occurrence of highly malignant neuroendocrine cancers. Cancer Res
2011; 71: 5987-5997.
9. Conti P, Castellani ML, Kempuraj D, Salani V, Vecchiet J, Tete S, Mastrangelo F,
Parrella A, Lutiis MAD, Tangen M, Theoharides TC. Role of mast cells in tumour
growth. Ann Clin Lab Sci 2007; 34(4): 315-21.
10. Stawerski P, Wagrowska-Danilewicz M, Stasikowska-Kanicka O, Tuka E,
Danilewicz M. Augmented mast cell infiltration and microvessel density in prostate
cancer. Contemp Oncol 2013; 17:378.
11. Li L, Dang Q, Xie H, Yang Z, He L, Liang L, Song W, Yeh S et al. Infiltrating mast
cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen
receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
Oncotarget 2015;6 : 14179–90.
12. Amir T, Pai RR, Raghuveer CV. Mast Cell Profile in Prostatic Lesions. Indian J Med
Sci 1998; 52:507-13.
13. Rakshith V, Kumar ML. Study of mast cells in prostate lesions: Adenocarcinoma
compared with hyperplasia. Clin Cancer Investig J 2016; 5:121-5
14. Aydin O, Dusmez D, Cinel L, Doruk E, Kanik A. Immunohistological analysis of
mast cell numbers in the intratumoral and peritumoral regions of prostate carcinoma
compared to benign prostatic hyperplasia. Pathol Res Pract.2002; 198: 267-71.
15. Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J et al. Mast
cells are novel independent prognostic markers in prostate cancer and represent a
target for therapy. Am J Pathol 2010; 177: 1031–1041.
of medical physiology. New York: McGraw-Hill Medical: 2005.p.63-78.
2. Globa T, Şaptefrţi L, Ceauşu RA, Gaje P, Cimpean AM, Raica M. Mast cell
phenotype in benign and malignant tumors of the prostate. Pol JPathol 2014;
2:147–153.
3. Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth.
Trends Immunol 2004; 25:235–241.
4. Gupta RK. Mast cell variations in prostate and urinary bladder. Arch Pathol
1970; 89:302–305.
5. Sari A, Serel TA, Çandir Ö, Öztürk A, Kosar A. Mast cell variations in tumour tissue
and with histopathological grading in specimens of prostatic adenocarcinoma. BJU
Int 1999; 84: 851-853
6. Strasner A, Karin M. Immune infiltration and prostate cancer. Front Oncol 2015;
5:128.
7. Crivellato E, Nico B, Ribatti D. Mast cell contribution to tumor angiogenesis: a clinical
approach.Eur Cytokine Netw 2009; 20:197–206.
8.Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M, Rigoni A et al. Mast cell
targeting hampers prostate adenocarcinoma development but promotes the
occurrence of highly malignant neuroendocrine cancers. Cancer Res
2011; 71: 5987-5997.
9. Conti P, Castellani ML, Kempuraj D, Salani V, Vecchiet J, Tete S, Mastrangelo F,
Parrella A, Lutiis MAD, Tangen M, Theoharides TC. Role of mast cells in tumour
growth. Ann Clin Lab Sci 2007; 34(4): 315-21.
10. Stawerski P, Wagrowska-Danilewicz M, Stasikowska-Kanicka O, Tuka E,
Danilewicz M. Augmented mast cell infiltration and microvessel density in prostate
cancer. Contemp Oncol 2013; 17:378.
11. Li L, Dang Q, Xie H, Yang Z, He L, Liang L, Song W, Yeh S et al. Infiltrating mast
cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen
receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
Oncotarget 2015;6 : 14179–90.
12. Amir T, Pai RR, Raghuveer CV. Mast Cell Profile in Prostatic Lesions. Indian J Med
Sci 1998; 52:507-13.
13. Rakshith V, Kumar ML. Study of mast cells in prostate lesions: Adenocarcinoma
compared with hyperplasia. Clin Cancer Investig J 2016; 5:121-5
14. Aydin O, Dusmez D, Cinel L, Doruk E, Kanik A. Immunohistological analysis of
mast cell numbers in the intratumoral and peritumoral regions of prostate carcinoma
compared to benign prostatic hyperplasia. Pathol Res Pract.2002; 198: 267-71.
15. Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J et al. Mast
cells are novel independent prognostic markers in prostate cancer and represent a
target for therapy. Am J Pathol 2010; 177: 1031–1041.
Published
2018-11-30
Issue
Section
Original Article
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
